Once we receive favourable (fingers crossed!) results from the Perth Burns Unit Phase I/II topical study by the end of March, then I truly believe we will never look back.
@Gitmo mentioned BD1 (BARD1 Life Sciences), whose SP went absolutely nuts a fortnight ago on release of good results. But subsequently, its SP has halved I note. Where RCE differs from BD1, is that it has up its sleeve a program of announcements (for its range of its products) to release throughout 2021. Momentum will build, surely. Which is why I'm picking a $4 SP by December. DYOR
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.020(6.90%) |
Mkt cap ! $89.39M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 32.8¢ | 29.0¢ | $78.39K | 251.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 916 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 114230 | 1 |
View Market Depth
| Last trade - 15.59pm 25/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |